Basic Cipramil Information

• INN (International Nonproprietary Name): Citalopram
• Brand Names Available In United Kingdom: Cipramil and generic citalopram (10 mg, 20 mg, 40 mg)
• ATC Code: N06AB04
• Forms & Dosages: Tablets 10 mg, 20 mg, 40 mg; oral solution 10 mg/mL in some regions
• Manufacturers In United Kingdom: Not specified
• Registration Status In United Kingdom: Prescription only; authorised and appears in NHS formularies
• OTC / Rx Classification: Prescription only (Rx)

Key Findings From Recent Trials

Major 2022–2025 Studies

What should clinicians know from the latest trials about citalopram efficacy and safety?

Large randomised controlled trials and pooled analyses published through 2024 and into 2025 continued to place citalopram alongside other SSRI antidepressants for adult major depressive disorder.

Head-to-head comparisons in adults showed generally similar short-term antidepressant response versus sertraline and escitalopram, with no consistent superiority for symptom reduction.

Systematic reviews and network meta-analyses reaffirm earlier effect sizes for citalopram in major depressive disorder.

Main Outcomes

Response and remission rates for citalopram were modest but clinically meaningful compared with placebo in adults with MDD.

Differences between SSRIs were seen more in tolerability and side-effect profiles than in core antidepressant effect.

Meta-analytic work highlighted gastrointestinal adverse events and sexual dysfunction as frequent causes of discontinuation.

Safety Observations

Regulatory reviews between 2018 and 2024 increased scrutiny of dose-dependent QT prolongation linked to citalopram, informing current UK dose ceilings.

Observational cohorts noted higher adverse-event rates among older adults and CYP2C19 poor metabolisers.

Guidance now recommends a 40 mg/day adult maximum and a 20 mg/day ceiling for elderly people, those with hepatic impairment and confirmed CYP2C19 poor metabolisers.

Clinical Mechanism Of Action

Layman’s Explanation

How does cipramil help lift mood in an everyday sense?

Citalopram increases serotonin availability in the brain by blocking its reuptake at nerve endings, which can improve mood and reduce anxiety over a few weeks.

Most people notice mood changes between two and six weeks, though some physical symptoms such as nausea can appear earlier.

Scientific Breakdown

Citalopram is a selective serotonin reuptake inhibitor (SSRI, ATC N06AB04) that binds the serotonin transporter (SERT) and reduces presynaptic reuptake of 5‑HT.

Oral tablets and oral solution formulations (10, 20, 40 mg) are well absorbed and undergo hepatic metabolism involving CYP2C19, CYP3A4 and CYP2D6 to inactive metabolites.

Although synaptic serotonin rises quickly, therapeutic antidepressant effects typically require adaptive neuronal and receptor changes over 2–6 weeks.

Dose-dependent blockade of cardiac hERG channels underlies citalopram’s QT prolongation risk, which is why regulatory dose limits exist.

Interactions are driven by CYP inhibitors/inducers and additive serotonergic or QT‑prolonging medications.

Scope Of Approved And Off-Label Use

United Kingdom Approvals

Is cipramil licensed for depression in the UK and where does it sit in guidelines?

Citalopram is licensed for major depressive disorder and features in NHS formularies as a commonly used SSRI option.

NICE and primary-care pathways list SSRIs as first-line antidepressants, and citalopram is a typical choice when clinically appropriate.

Product availability in the UK commonly includes Cipramil and generic citalopram tablets in 10 mg, 20 mg and 40 mg strengths.

Notable Off-Label Trends

Which other conditions might clinicians prescribe citalopram for outside its licence?

Prescribers sometimes use citalopram off-label for anxiety spectrum disorders such as generalised anxiety disorder and panic disorder, and occasionally for obsessive–compulsive disorder.

Clinical practice varies by clinician and local formulary, and citalopram is generally avoided in under‑18s because of a raised risk of suicidality.

Treatment duration follows standard guidance: assess at 4–6 weeks, and plan maintenance commonly for 6–12 months after symptom control.

Dosage Strategy

General Dosing

What starting dose should most adults expect when prescribed cipramil?

The usual adult starting dose for major depressive disorder is 20 mg once daily, with a typical maintenance range of 20–40 mg once daily.

A maximum of 40 mg/day is recommended for adults because of QT prolongation risk.

Elderly people (>60 years), those with hepatic impairment and confirmed CYP2C19 poor metabolisers should usually remain at or below 20 mg once daily.

Condition-Specific Dosing

Are there adjustments for anxiety or severe depression?

When used for anxiety-spectrum disorders, prescribers commonly start at 20 mg and may titrate more slowly to help tolerability.

For severe MDD some clinicians cautiously increase toward 40 mg if clinically indicated and with ECG monitoring where cardiac risk is present.

Renal impairment (mild–moderate) usually does not require routine dose adjustment, but severe renal data are limited so monitor closely.

Tapering should be gradual to reduce withdrawal symptoms such as dizziness and sensory disturbances.

Safety Protocols

Contraindications

Who should not take cipramil under any circumstances?

Absolute contraindications include concomitant monoamine oxidase inhibitors (MAOIs), pimozide, and known hypersensitivity to citalopram or excipients.

Relative cautions include congenital or acquired long QT, bradycardia, electrolyte disturbances and recent acute myocardial infarction.

Seizure disorders require caution because citalopram may lower the seizure threshold.

Adverse Effects

What side effects do patients commonly report with citalopram?

Very common reactions include nausea and dry mouth.

Common adverse effects include drowsiness or insomnia, increased sweating, tremor, diarrhoea and sexual dysfunction (decreased libido, anorgasmia, erectile dysfunction).

Less common but notable risks are dose‑dependent QT prolongation, hyponatraemia or SIADH—particularly in older adults—and serotonin syndrome with other serotonergic drugs.

Monitor bleeding risk when citalopram is combined with anticoagulants or NSAIDs.

Interaction Mapping

Food Interactions

Are there foods to avoid while taking cipramil?

There are no major dietary restrictions, but alcohol can worsen sedation and may reduce antidepressant effectiveness, so patients should avoid excess alcohol.

Drug Combinations To Avoid

Which medicines cause the highest-risk interactions with citalopram?

Avoid MAOIs because of serotonin syndrome risk, and stop MAOIs or wait 14 days when switching to or from citalopram.

Pimozide is contraindicated due to additive QT prolongation.

Strong CYP2C19 inhibitors can raise citalopram levels and require dose review; other serotonergic drugs (triptans, other SSRIs, SNRIs) increase serotonin syndrome risk.

Reconcile any QT‑prolonging agents such as certain antipsychotics, antiarrhythmics and some antibiotics before dosing above usual levels.

Always check a current national interaction checker and local formulary before initiating or changing therapy.

Patient Experience Analysis

Survey Data

What do patients say about taking cipramil in real life?

Survey reports and service‑user feedback consistently show many patients notice mood improvements within 2–6 weeks.

However, tolerability issues—especially nausea and sexual dysfunction—are frequent reasons for stopping treatment.

Older adults often report increased fatigue or cognitive dulling, while younger adults sometimes experience insomnia or agitation early on.

Forum Trends

How do online communities describe switching or stopping citalopram?

Forum discussions highlight wide individual variability in tolerability and frequent conversations about switching SSRIs when sexual side effects occur.

Withdrawal experiences after abrupt stopping commonly include dizziness, “electric” sensations and mood lability, which supports the need for slow tapering.

Good clinician communication, shared decision‑making and anticipatory side‑effect guidance improve adherence in real-world practice.

Distribution & Pricing Landscape

Where can patients find cipramil and what affects price and availability in the UK?

Citalopram is widely available globally under brand names such as Cipramil and Celexa and as many generics from manufacturers like ratiopharm, Sandoz, Zentiva and Mylan.

In the United Kingdom, generic citalopram dominates NHS prescribing because of cost-effectiveness, with brand prescribing in selected cases.

Generic tablet pricing is generally low on NHS formularies, while brand products carry a premium where used.

Supply is usually stable due to multiple global manufacturers, but local shortages can occur and should be checked via MHRA and NHS England notices.

In our online pharmacy, cipramil is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Alternative Options

Comparison Table

Pros And Cons

How should clinicians choose between citalopram and alternatives?

Escitalopram may offer marginal tolerability advantages in some studies, while sertraline is often preferred for anxiety indications in UK primary care.

Fluoxetine’s long half‑life can help adherence and reduce withdrawal risk, whereas paroxetine is associated with weight gain and more pronounced withdrawal.

SNRIs can be better when neuropathic pain is present but may carry greater discontinuation symptoms than SSRIs.

Cardiac disease, drug–drug interactions, age, pregnancy status and prior response history should guide the choice in shared decision‑making.

Regulatory Status

What do regulators say about cipramil and where can prescribers check up‑to‑date guidance?

Citalopram is authorised by EMA member states and was approved by the FDA in 1998 for adult depression.

In the United Kingdom it is prescription-only and included in NHS formularies in generic and branded forms.

Regulatory safety updates have emphasised QT prolongation concerns and set the adult maximum at 40 mg/day and 20 mg/day for elderly people, hepatic impairment and CYP2C19 poor metabolisers.

Prescribers should consult the SmPC, MHRA guidance and national formularies for current contraindications, ECG advice and pregnancy/breastfeeding recommendations.

Suspected adverse reactions should be reported via the Yellow Card scheme to support pharmacovigilance.

Consolidated FAQ

Common Prescriber Questions

Can patients drive while taking cipramil?

Most patients can drive, but if experiencing sedation, dizziness or impaired concentration they should not drive until symptoms resolve.

Is an ECG required before starting citalopram?

Consider a baseline ECG for patients with known cardiac disease, electrolyte disturbances, or those taking other QT‑prolonging drugs, and before escalating toward 40 mg in at‑risk individuals.

How should CYP2C19 poor metabolisers be managed?

Limit dosing to 20 mg once daily for confirmed CYP2C19 poor metabolisers as advised in product information.

Patient-Focused Q&As

How long until I feel better on cipramil?

Clinical effects typically emerge between two and six weeks; review at four to six weeks to assess response.

What happens if I miss a dose?

Take a missed dose as soon as remembered unless the next dose is near—do not double up.

How should I stop citalopram?

Taper gradually under clinical supervision to reduce the likelihood of withdrawal symptoms such as dizziness and sensory disturbances.

Is citalopram safe in pregnancy or breastfeeding?

Use a risk–benefit assessment and discuss options with obstetric and mental‑health specialists, referring to the SmPC for details.

Visual Guide

Suggested Diagrams

Which visuals help clinicians explain citalopram to patients?

A mechanism diagram showing SERT blockade and increased synaptic serotonin gives patients a clear mental model of SSRI action.

A dosing flowchart that starts at 20 mg, shows assessment points at 4–6 weeks and annotates UK‑specific dose limits (max 40 mg; elderly/hepatic/CYP2C19 poor metabolisers 20 mg) supports safe titration.

An ECG risk checklist that lists age, cardiac history, electrolytes and interacting drugs helps determine when to arrange monitoring.

Patient Handout Elements

What should a one‑page patient leaflet include?

List brand and generic names (Cipramil, citalopram), common side effects, missed‑dose instructions and overdose advice.

Add storage advice (store at 20–25°C), Yellow Card reporting link and contact numbers for urgent concerns.

Use plain language, large fonts and colour coding for common versus serious side effects to support shared decision‑making.

Storage & Transport

Practical Handling

How should citalopram products be stored in pharmacy and at home?

Store tablets and oral solution at 20–25°C in the original packaging to protect from moisture and light.

Advise patients to keep medicines away from children and to return unused medication to the pharmacy for safe disposal.

Manufacturer Guidance

Are there special transport requirements for citalopram?

Citalopram is not a controlled substance and is transported via normal pharmaceutical logistics under ambient conditions in line with local wholesale regulations.

Packaging varies internationally and may show names such as Citalopramum or Citalopramhydrobromid in some EU markets.

Guidelines For Proper Use

Initiation Checklist

What should be done before starting cipramil?

Confirm the indication of major depressive disorder and review current medications for MAOIs, pimozide, CYP inhibitors and QT‑prolonging agents.

Assess cardiac history and consider baseline electrolytes and an ECG if risk factors are present.

Discuss common side effects including GI upset and sexual dysfunction and document shared decision‑making.

Monitoring Schedule

What follow‑up is recommended after starting treatment?

Review tolerability at two to four weeks and efficacy at four to six weeks.

If dose escalation is considered, repeat ECG when moving toward the 40 mg adult limit or when adding interacting drugs.

Monitor sodium in older adults at risk of hyponatraemia and watch for emergent suicidality in patients under 25 or those with risk factors.

When stopping, taper gradually over weeks and document the discontinuation plan and any Yellow Card reports for unexpected adverse reactions.

Delivery Across United Kingdom